Cargando…

A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy

BACKGROUND: It remains unclear how information about aromatase inhibitors (AI) impacts women’s decision-making about persistence with endocrine therapy. PURPOSE: To describe and compare how women treated for primary early stage breast cancer either persisting or not persisting with an AI received, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Pieters, Huibrie C., Green, Emily, Khakshooy, Sally, Sleven, Miriam, Stanton, Annette L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354984/
https://www.ncbi.nlm.nih.gov/pubmed/30703119
http://dx.doi.org/10.1371/journal.pone.0210972
_version_ 1783391282281840640
author Pieters, Huibrie C.
Green, Emily
Khakshooy, Sally
Sleven, Miriam
Stanton, Annette L.
author_facet Pieters, Huibrie C.
Green, Emily
Khakshooy, Sally
Sleven, Miriam
Stanton, Annette L.
author_sort Pieters, Huibrie C.
collection PubMed
description BACKGROUND: It remains unclear how information about aromatase inhibitors (AI) impacts women’s decision-making about persistence with endocrine therapy. PURPOSE: To describe and compare how women treated for primary early stage breast cancer either persisting or not persisting with an AI received, interpreted, and acted upon AI-related information. DESIGN: Thematic analysis was used to sort and compare the data into the most salient themes. PARTICIPANTS: Women (N = 54; 27 persisting, 27 not persisting with an AI) aged 65–93 years took part in qualitative interviews. RESULTS: Women in both subgroups described information similarly in terms of its value, volume, type, and source. Aspects of AI-related information that either differed between the subgroups or were misunderstood by one or both subgroups included: (1) knowledge of AI or tamoxifen prior to cancer diagnosis, (2) use of online resources, (3) misconceptions about estrogen, hormone replacement therapies and AI-related symptoms, and (4) risk perception and the meaning and use of recurrence statistics such as Oncotype DX. CONCLUSIONS: Persisters and nonpersisters were similar in their desire for more information about potential side effects and symptom management at AI prescription and subsequent appointments. Differences included how information was obtained and interpreted. Interactive discussion questions are shared that can incorporate these findings into clinical settings.
format Online
Article
Text
id pubmed-6354984
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-63549842019-02-15 A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy Pieters, Huibrie C. Green, Emily Khakshooy, Sally Sleven, Miriam Stanton, Annette L. PLoS One Research Article BACKGROUND: It remains unclear how information about aromatase inhibitors (AI) impacts women’s decision-making about persistence with endocrine therapy. PURPOSE: To describe and compare how women treated for primary early stage breast cancer either persisting or not persisting with an AI received, interpreted, and acted upon AI-related information. DESIGN: Thematic analysis was used to sort and compare the data into the most salient themes. PARTICIPANTS: Women (N = 54; 27 persisting, 27 not persisting with an AI) aged 65–93 years took part in qualitative interviews. RESULTS: Women in both subgroups described information similarly in terms of its value, volume, type, and source. Aspects of AI-related information that either differed between the subgroups or were misunderstood by one or both subgroups included: (1) knowledge of AI or tamoxifen prior to cancer diagnosis, (2) use of online resources, (3) misconceptions about estrogen, hormone replacement therapies and AI-related symptoms, and (4) risk perception and the meaning and use of recurrence statistics such as Oncotype DX. CONCLUSIONS: Persisters and nonpersisters were similar in their desire for more information about potential side effects and symptom management at AI prescription and subsequent appointments. Differences included how information was obtained and interpreted. Interactive discussion questions are shared that can incorporate these findings into clinical settings. Public Library of Science 2019-01-31 /pmc/articles/PMC6354984/ /pubmed/30703119 http://dx.doi.org/10.1371/journal.pone.0210972 Text en © 2019 Pieters et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Pieters, Huibrie C.
Green, Emily
Khakshooy, Sally
Sleven, Miriam
Stanton, Annette L.
A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy
title A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy
title_full A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy
title_fullStr A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy
title_full_unstemmed A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy
title_short A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy
title_sort qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354984/
https://www.ncbi.nlm.nih.gov/pubmed/30703119
http://dx.doi.org/10.1371/journal.pone.0210972
work_keys_str_mv AT pietershuibriec aqualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy
AT greenemily aqualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy
AT khakshooysally aqualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy
AT slevenmiriam aqualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy
AT stantonannettel aqualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy
AT pietershuibriec qualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy
AT greenemily qualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy
AT khakshooysally qualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy
AT slevenmiriam qualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy
AT stantonannettel qualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy